Skip to content

Newsroom

All News
  • All News
  • In the News
  • Press Releases
  • Publications
  • Events
Plos-medicine (1)

A Molecular Host Response Assay to Discriminate Between Sepsis and Infection-Negative Systemic Inflammation in Critically Ill Patients: Discovery and Validation in Independent Cohorts

McHugh et al., PLOS Medicine | SeptiCyte Lab is a rapid molecular assay that may be clinically useful in managing ICU patients with systemic inflammation. Further study in population-based cohorts is needed to validate this assay for clinical use.
Immunexpress.com

Immunexpress Releases Key Performance Data on SeptiCyte™ LAB in PLOS Medicine Publication

SEATTLE, Dec. 8, 2015 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, announced today the publication of the discovery and validation of the SeptiCyte® Lab test for sepsis in PLOS Medicine. SeptiCyte® Lab is a rapid molecular assay that measures a patient's gene expression...
Immunexpress.com

Immunexpress Appoints Dr. Roy Davis Chief Medical Officer

SEATTLE, Oct. 22, 2015 – Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced the  appointment of Roy F. J. Davis, Ph.D., M.D., M.H.A., as Chief Medical Officer. “Dr. Davis has over 30 years of experience providing and directing patient care for multiple...
Immunexpress.com

Immunexpress Appoints Dr. Bea Arnold to Board of Directors

SEATTLE, Sept. 29, 2015 – Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that Dr. Bea Arnold has joined the Company's Board of Directors. “We are delighted to welcome Dr. Arnold to our Board of the Directors,” said Roslyn Brandon, President and...
Immunexpress.com

Immunexpress to Present Data on SeptiCyte™ at the “Meeting of Experts on Biomarkers to Discriminate Bacterial from Other Infectious Causes of Acute Fever”

SEATTLE, Sept. 16, 2015 –  Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, announced today that Dr. Therese Seldon, Vice President of Operations, will present data on SeptiCyte® technology at the “Meeting of Experts on Biomarkers to Discriminate Bacterial from Other Infectious Causes of...
Immunexpress.com

Immunexpress Supports World Sepsis Day 2015

Call for Action on Sept. 13 Includes Awareness, Education and Funding Initiatives to Help Reverse Global Increase in Numbers of Deaths from Sepsis    Video Interviews on the Immunexpress Website Highlight the Need for Faster Diagnosis of Sepsis  SEATTLE, Sept. 10, 2015 –  Immunexpress, Inc., a molecular diagnostic company committed...
Immunexpress.com

Immunexpress to Present Data on the Early Diagnosis of Sepsis with SeptiCyte™ LAB at the Next Generation Diagnostics Summit

SEATTLE, Aug. 12, 2015 – Immunexpress, Inc. today announced that Dr. Therese Seldon, Vice President of Operations, will present data on the utility of its SeptiCyte® Lab test to aid in the clinical assessment of sepsis in critical care patients at the Next Generation Diagnostics Summit on Aug. 19 in...
Immunexpress.com

Immunexpress to Present Data on Utility of SeptiCyte™ LAB for Diagnosing Sepsis at the Pathology Diagnostics Conference

Immunexpress to Present Data on Utility of SeptiCyte™ Lab for Diagnosing Sepsis at the Pathology Diagnostics Conference SeptiCyte™ Lab Quantifies Host Molecular Markers to Aid Physicians in the Diagnosis of Sepsis in Critical Care Patients SEATTLE, June 4, 2015 – Immunexpress, Inc. today announced that Dr. Antony Rapisarda, Director Medical...
genome web

Immunexpress to Submit Molecular ‘Immune Response’ Sepsis Assay to FDA in May

Immunexpress may finally be close to marketing a clinical test in the US. Having just wrapped up a key clinical trial of its first sepsis assay in around 200 ICU patients, the company plans to submit the test in May to the US Food and Drug Administration and hopes it can...
bioworld-logo

Immunexpress vying for FDA clearance of its sepsis test

When it comes right down to detecting sepsis most diagnostics companies use methods to identify the pathogen. But therein lies the issue with looking for the pathogen, because it has to be in the blood sample or the fluid sample to start with, otherwise a clinician can't find. That's where...
Medcity-news

Immunexpress raising $40M; measures immune response to shave sepsis diagnostic time to one hour

Seattle diagnostics company Immunexpress is working to whittle sepsis screening time down to an hour – and is in the midst of a $40 million Series C to do so.
Immunexpress.com

Immunexpress Receives Early Stage Commercialisation Support to Further Develop SeptiCyte® PLUS

Immunexpress receives Early Stage Commercialisation support to further develop SeptiCyte®PLUS — designed to diagnose sepsis accurately within a clinically relevant timeframe. BRISBANE, Australia (February 18, 2014) – Today, Immunexpress Group (Immunexpress) announced it has received Early Stage Commercialisation support through Commercialisation Australia, an initiative of the Australian Government. The AUD...

If you are a member of the media, please contact:

Maggie Beller
Russo Partners
(646) 942-5631
maggie.beller@russopartnersllc.com

Scroll To Top